|
|
|
|
||
Re: dougheuring tweet@dougheuringaria: CS PE Valuation of Top 25 Global Phama/Biotech Companies by Market Cap $GILD $CELG $MRK $BMY $IBB $JNJPfizer is foolish not to take a run at Celgene, or a smaller company like Acadia. Obviously not saying it will happen, but typical of Blue Chip Boards. Looking for back room, cost reducing synergies and/or tax saving, off-shore corporate registration opportunities in acquisition candidates, rather than growth. Pfizer working on #3 incompetent CEO after being an innovator for 25 years with an incredible pipeline. Having said that, pfe is a good holding as a dividend stock, IMO. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
199609 | Re: dougheuring tweet@dougheuringaria: CS PE Valuation of Top 25 Global Phama/Biotech Companies by Market Cap $GILD $CELG $MRK $BMY $IBB $JNJ | schull | 0 | 8/28/2015 10:38:58 AM |